GHK-Cu vs NAD+

How GHK-Cu and NAD+ differ

GHK-Cu and NAD+ are different molecules. GHK-Cu is a copper coordination complex: the tripeptide GHK holding a single copper ion. NAD+ is nicotinamide adenine dinucleotide, a dinucleotide rather than a peptide.^[2] It consists of two nucleotide units joined through a pyrophosphate bridge. The plus sign in its name denotes a permanent positive charge on the nitrogen of its nicotinamide ring.

In the literature reviewed for GHK-Cu, copper-loaded GHK-Cu and metal-free GHK are different test articles, and paper titles do not always make the difference clear. Some of the newer cell and animal work in that literature used metal-free GHK instead. In the literature reviewed for NAD+, a much larger body of work concerns two precursors, nicotinamide riboside and nicotinamide mononucleotide.^[6][7] The two precursors are chemically distinct from NAD+, so a trial of either is not evidence about NAD+.^[6][7]

For GHK-Cu, most of what is known comes from cell culture and animal models. Two controlled human trials isolated a copper tripeptide preparation as the variable, and both were negative on their objective endpoints. Other human reports on GHK-Cu are case reports, single-arm studies or trials of multi-ingredient formulations. In those designs it cannot be separated from the other active ingredients. One body of the cell and animal work comes substantially from one research group. That body of work used the copper complex throughout, and so did both controlled human trials. The compound's original discoverer, a commercially interested party, appears across the early work. The literature reviewed for GHK-Cu reports no human safety data.

In the literature reviewed for NAD+, the human studies of NAD+ itself are one randomized trial, one pharmacokinetic pilot and one retrospective record review.^[3][8][9] The trial, in one indication, was single-center and has not been replicated.^[3] Its primary endpoint was a surrogate imaging measure rather than a hard clinical outcome.^[3] The pilot had three controls, and it reported no clinical outcome.^[8] It was partly funded by a business with a commercial interest in NAD+ and run at a clinic with the same interest, and one author held roles at both.^[8] The review was written by employees of a company with a commercial interest in NAD+, whose records it reviewed.^[9] In the retrospective record review, which was not randomized, people exposed to NAD+ reported moderate to severe gastrointestinal symptoms, raised heart rate and chest pressure.^[9]

GHK-Cu holds no FDA approval. NAD+ holds no FDA approval.^[4]

GHK-Cu's vulnerable feature is its metal-ligand bond, which competing chelators and pH extremes dissociate. NAD+ has no metal center. NAD+ has two structural weak points, and they fail under opposite conditions. Acid cleaves its pyrophosphate bridge into two mononucleotide halves. Alkaline conditions instead cleave the glycosidic bond that holds its nicotinamide to a ribose.

Have GHK-Cu and NAD+ been compared directly?

No direct comparison of GHK-Cu with NAD+ was found in a PubMed search run in October 2026.^[5] That search covers PubMed only.